Long-term safety of dapirolizumab pegol in people with lupus
Tests dapirolizumab pegol's long-term safety in people with systemic lupus erythematosus.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Key facts
- Where
- A Coruña, Badajoz, Barcelona, Castello De La Plana, Madrid, Málaga, Mérida, Murcia, Sabadell, San Cristobal De La Laguna, Santander, Santiago de Compostela, Sevilla, Vigo, and Vitoria, SpainSee the 20 sites
- Phase
- Phase 3
Where in Spain
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
- Hospital Universitario de BadajozBadajoz, SpainTaking people
- Hospital de la Santa Creu i Sant PauBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital General Universitario De CastellonCastello De La Plana, SpainTaking people
- Futuremeds Spain S.L.Madrid, SpainTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainTaking people
- Hospital de MéridaMérida, SpainTaking people
- University Clinical Hospital Virgen De La ArrixacaMurcia, SpainTaking people
- Parc Tauli Hospital UniversitariSabadell, SpainTaking people
- University Hospital Of Canary IslandsSan Cristobal De La Laguna, SpainTaking people
- Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
- Clínica Gaias - SantiagoSantiago de Compostela, SpainTaking people
- Hospital Quironsalud Infanta LuisaSevilla, SpainTaking people
- Hospital Quironsalud Sagrado CorazonSevilla, SpainTaking people
- Hospital Universitario Virgen De La MacarenaSevilla, SpainTaking people
- Hospital Universitario Virgen De ValmeSevilla, SpainTaking people
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
- Complexo Hospitalario Universitario De VigoVigo, SpainTaking people
- Hospital Universitario ArabaVitoria, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UCB Biopharma SRL
- Trial code
- NCT04976322EU 2023-506368-14-00
- Record updated
- 15 October 2026
- Original description
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.Read full original descriptionShow less
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
Inclusion: The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment; The participant completed one of the parent studies within 4 weeks prior to entry to this study.
Exclusion: Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study.